Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies
This article was originally published in The Gray Sheet
Executive Summary
The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.